ArticleMycopathologia2025
Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hyperkeratotic tinea pedis is a treatment-resistant infection. We evaluated the efficacy of a 3-month course of topical 1% luliconazole in 21 hyperkeratotic tinea pedis patients. The diagnosis was confirmed through microscopy and culture. The lesion area was assessed monthly using a software program. Clinical responses were classified into five categories from "cured" to "no change." Among the isolates, one terbinafine-resistant T. rubrum strain was detected. The mean lesion area decreased significantly over 3 months, with an average improvement rate of 94.1% ± 12.7% and a cure rate of 61.9%. The mean amount of luliconazole used per foot was 27.5 ± 9.7 g monthly. The resistant case showed a partial improvement with topical luliconazole and was successfully treated with oral fosravuconazole. These findings suggest that 1% topical luliconazole is effective for treating hyperkeratotic tinea pedis.
Indexed as
Identifiers
40696008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.